Kangwei Century (688426.SH): Has repurchased 0.7549% of the company's shares
Gelonghui, May 6, 丨 Kang Wei Century (688426.SH) announced that by the close of trading on April 30, 2024, the company had repurchased a total of 849,219 shares through the Shanghai Stock Exchange trading system, accounting for 0.7549% of the company's total share capital of 112,493,716 shares. The highest price for the repurchase transaction was 22.48 yuan/share, the lowest price was 17.50 yuan/share, and the total amount of capital paid was RMB 17,055,958.34 (excluding transaction fees such as stamp duty and transaction fees).
Kangwei Century (688426.SH) announced first-quarter results with a net loss of 28.97 million yuan
Kang Wei Century (688426.SH) disclosed its report for the first quarter of 2024. The company achieved 288 revenue during the reporting period...
Kangwei Century (688426.SH) issued 2023 annual results with a net loss of 84.4095 million yuan
Kangwei Century (688426.SH) released its 2023 annual report. The company achieved operating income of 1 during the reporting period...
Kangwei Century (688426.SH): A total cost of 10.166 million yuan to buy back 0.4333% of the shares
Gelonghui, April 1, 丨 Kang Wei Century (688426.SH) announced that by the close of trading on March 29, 2024, the company had repurchased 487,427 shares of the company through centralized bidding transactions, accounting for 0.4333% of the company's total share capital of 112,493,716 shares. The highest price of the repurchase transaction was 22.48 yuan/share, the lowest price was 20.01 yuan/share, and the total amount of capital paid was RMB 10,166,439.03 (excluding transaction fees such as stamp duty and transaction fees).
Kangwei Century (688426.SH): First repurchase of 59,000 shares
Gelonghui, March 4, 丨 Kang Wei Century (688426.SH) announced that on March 4, 2024, Jiangsu Kangwei Century Biotechnology Co., Ltd. repurchased 59,262 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0528% of the company's total share capital of 112,227,568 shares. The highest price for the repurchase transaction was 21.64 yuan/share, and the lowest price was 20.98 yuan/share. The total amount of capital paid was RMB 1,274,479.33.
Kangwei Century (688426.SH): net loss of 81.013,600 yuan in 2023
Gelonghui, Feb. 27丨Kang Wei Century (688426.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 177.455,800 yuan, a year-on-year decrease of 65.98%; realized total profit of -86.773,900 yuan, a year-on-year decrease of 144.41%; realized net profit attributable to owners of the parent company - 81.013,600 yuan, a year-on-year decrease of 150.87%; realized net profit attributable to owners of the parent company - 116.5982 million yuan, a year-on-year decrease of 116.5982 million yuan, a year-on-year decrease of 116.5982 million yuan. 178.31%
Kangwei Century (688426.SH): Plans to buy back 30 million yuan to 60 million yuan of company shares
Gelonghui, Feb. 6: Kang Wei Century (688426.SH) announced that the proposed repurchase scale will not be less than RMB 30 million, no more than RMB 60 million of the company's shares, and the repurchase price will not exceed RMB 25.88 per share.
Jiangsu CoWin Biotech Co., Ltd.'s (SHSE:688426) 37% Share Price Plunge Could Signal Some Risk
The Jiangsu CoWin Biotech Co., Ltd. (SHSE:688426) share price has fared very poorly over the last month, falling by a substantial 37%. For any long-term shareholders, the last month ends a year to
Kang Wei (688426.SH) issued a forecast loss. The net loss is expected to be 75 million yuan to 90 million yuan in 2023, changing from profit to loss over the same period last year
According to Zhitong Finance App News, Kang Wei Century (688426.SH) announced that the company expects to achieve a loss in 2023 net profit attributable to the owner of the parent company compared with the same period last year. The net profit attributable to the owner of the parent company is a loss of 75 million yuan to 90 million yuan, a decrease of 147.09% to 156.51% compared with the same period last year. Net profit attributable to owners of the parent company in 2022:15.9258,900 yuan. During the reporting period, it was affected by factors such as domestic and foreign macroeconomic environments, changes in health prevention and control policies, and changes in market demand in the molecular testing industry
Kangwei Century (688426.SH) released the first three quarter results, with a net loss of 355.46,400 yuan
Kangwei Century (688426.SH) released its report for the third quarter of 2023. The company achieved revenue of 1 in the first three quarters...
Kangwei Century (688426.SH) 11.753,900 restricted shares will be listed and distributed on October 25
Kang Wei Century (688426.SH) announced that the number of restricted shares currently listed and in circulation of the company is 11.753,900 shares...
Jiangsu Cowin Biotech's Unit Gets Nod for Registration of Blood Detection Kit
Jiangsu Cowin Biotech's (SHA:688426) unit, Jiangsu Jianwei Diagnostic Technology, received a registration certificate from the food and drug administration of China's Jiangsu Province for its fecal bl
Kang Wei Century (688426.SH): Fecal occult blood test kit (colloidal gold method) obtained a Class II medical device registration certificate
Kangwei Century (688426.SH) announced that Jiangsu Jianwei Diagnostic Technology Co., Ltd., a wholly-owned subsidiary of the company (“Jianwei...
Kang Wei Century (688426.SH): Net loss of 9.8736 million yuan in the first half of the year
GLONGHUI, August 29 | Kang Wei Century (688426.SH) announced the 2023 semi-annual report. During the reporting period, it achieved operating income of 122 million yuan, a decrease of 54.23%; net loss attributable to shareholders of listed companies was 9.8736 million yuan, converted to loss year over year; net loss attributable to shareholders of listed companies was 21.2434 million yuan per share after deducting non-recurring profit and loss; net loss of 21.2434 million yuan per share attributable to shareholders of listed companies.
Jiangsu CoWin Biotech Co., Ltd.'s (SHSE:688426) Stock Is Going Strong: Have Financials A Role To Play?
Most readers would already be aware that Jiangsu CoWin Biotech's (SHSE:688426) stock increased significantly by 13% over the past week. Given that stock prices are usually aligned with a company's f
Jiangsu CoWin Biotech's (SHSE:688426) Solid Earnings May Rest On Weak Foundations
Jiangsu CoWin Biotech Co., Ltd.'s (SHSE:688426) healthy profit numbers didn't contain any surprises for investors. However the statutory profit number doesn't tell the whole story, and we have found
Market Might Still Lack Some Conviction On Jiangsu CoWin Biotech Co., Ltd. (SHSE:688426) Even After 30% Share Price Boost
Jiangsu CoWin Biotech Co., Ltd. (SHSE:688426) shareholders would be excited to see that the share price has had a great month, posting a 30% gain and recovering from prior weakness. While recent bu
Express News | Jiangsu Cowin Biotech CFO Resigns; Deputy GM Named as Successor
No Data